Aquinox Pharmaceuticals, an early-stage biotech developing treatments for inflammation of the lung and bladder, raised $46 million by offering 4.2 million shares (upsized from 3.7 million) at $11, the midpoint of the $10 to $12 range. Aquinox Pharmaceuticals will list on the NASDAQ under the symbol AQXP. Jefferies and Cowen & Company acted as joint bookrunners on the deal.
